All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Amer ZeidanDuring the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked: What is the role of immune checkpoint directed therapy in the treatment of acute myeloid leukemia (AML)?
Amer Zeidan discusses a large randomized trial in patients with AML and myelodysplastic syndromes (MDS) investigating immune checkpoint blockade. In total, 213 patients were randomized to receive azacitidine (AZA) or AZA with an anti-PDL1 inhibitor durvalumab . Whilst the final results did not show a difference in overall response rate (ORR), it was noted that the study has provided invaluable information about how immune checkpoint blockade plays a role in AML.
What is the role of immune checkpoint directed therapy in the treatment of AML?
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?